Peptide Profile
CJC-1295 / Ipamorelin
GHRH Analog and Selective GHRP Combination
01
Overview
Composition
Research combination pairing a GHRH analog, usually CJC-1295 or modified GRF 1-29, with the selective ghrelin-receptor agonist ipamorelin
Mechanism of Action
CJC-1295/modified GRF stimulates pituitary growth hormone release through the GHRH receptor, while ipamorelin activates ghrelin/GHSR signaling; together they are used to amplify pulsatile GH release more than either signal alone
Primary Effects
Explored for GH/IGF-1 signaling, recovery, body composition, sleep quality, and tissue-repair support, with evidence mostly extrapolated from the individual compounds and small GH-secretagogue literature
02
Discovery & Background
The pairing comes from growth-hormone secretagogue research that combines hypothalamic GHRH signaling with ghrelin-receptor signaling.
CJC-1295 research established prolonged GH/IGF-1 elevation, especially with DAC. Ipamorelin was developed as a more selective GHRP with less prolactin/cortisol activity than older secretagogues.
No FDA-approved CJC/ipamorelin combination product exists
03
Research Overview
Combination rationale is mechanistic: simultaneous GHRH and GHSR stimulation can produce synergistic GH release, but standardized human trials of commercial CJC/ipamorelin blends are limited
- 01
CJC-1295 with DAC can sustain GH and IGF-1 elevations for days
- 02
Modified GRF 1-29 is shorter acting than the DAC-linked CJC-1295 form
- 03
Ipamorelin is studied as a selective GH secretagogue with comparatively low cortisol/prolactin stimulation
- 04
The commercial combination itself has far less direct trial evidence than the separate components
- 05
Long-term use may raise concerns about excessive IGF-1, edema, insulin resistance, or growth-related contraindications
Research-only/off-label; individual components are not approved for general wellness or routine aging use
04
Safety Considerations
Monitoring
- IGF-1
- Fasting glucose and A1c
- Edema, numbness/tingling, blood pressure, and sleep apnea symptoms
- Signs of excessive GH/IGF-1 activity
- Medication and cancer-history review
Side Effects
Endocrine/metabolic
- Water retention, edema, carpal-tunnel-like symptoms
- Increased hunger or changes in glucose tolerance
- Potential excessive IGF-1 elevation
Other reported
- Transient flushing or lightheadedness
- Headache, flushing, fatigue, or vivid dreams
Contraindications
- Active malignancy or unresolved cancer-risk concerns
- Uncontrolled diabetes or significant insulin resistance without medical oversight
- Pregnancy or breastfeeding
- Known hypersensitivity to either component
05
Educational Notice
Use medical supervision and lab monitoring for any clinical decision-making.
References
Research And Source List
Structured reference cards with source metadata and a direct link so users can inspect the original study/source.FDA review | 2024
Official review covering CJC-1295-related naming and safety concerns.JCEM | 2006
Human CJC-1295 study anchoring the GHRH-analog component.Eur J Endocrinol | 1998
Foundational selectivity paper for the ghrelin-secretagogue component.Pharmaceutical Research | 1999
Source metadata available through the linked record.JCEM | 2014
Human clinical-development trial relevant to safety and translational context.Drugs@FDA
FDA search entry point for labeled products, approval documents, and regulatory status checks.WADA
Current anti-doping source used for prohibited-in-sport review.American Journal of Physiology-Endocrinology and Metabolism | 2006
Preclinical CJC-1295 paper for long-acting GHRH analog context.PubMed indexed literature query
Search results for indexed publications and abstracts related to CJC-1295 / Ipamorelin.ClinicalTrials.gov
Trial-registry search for study status, sponsors, and registered human-research context.Pattern Store